Clinicopathological analysis of basal cell carcinoma of the anal region and its distinction from basaloid squamous cell carcinoma

Modern Pathology

Volumn 26, Issue 10, 2013, Pages 1382-1389

  Patil, Deepa T ^a   Goldblum, John R ^a   Billings, Steven D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anal; Basal cell carcinoma; Basaloid squamous cell carcinoma; Perianal; SOX2

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 5; CYTOKERATIN 6; PROTEIN BCL 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX2;

ADULT; AGED; ANUS BASAL CELL CARCINOMA; ANUS CARCINOMA; BASAL CELL CARCINOMA; BASALOID SQUAMOUS CELL CARCINOMA; CANCER LOCALIZATION; CANCER MORPHOLOGY; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CARCINOMA; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA;

AGED; ANUS NEOPLASMS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; HUMANS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; SOXB1 TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885018502     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.75     Document Type: Conference Paper

References (49)

1. Nielsen OV, Jensen SL. Basal cell carcinoma of the anus - a clinical study of 34 cases. Br J Surg 1981;68: 856-857.
2. Tellechea O, Reis JP, Domingues JC, et al. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin. Am J Dermatopathol 1993;15: 452-455.
3. Jones MS, Helm KF, Maloney ME. The immunohistochemical characteristics of the basosquamous cell carcinoma. Dermatol Surg 1997;23: 181-184.
4. Beer TW, Shepherd P, Theaker JM. Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology 2000;37: 218-223.
5. Cerroni L, Volkenandt M, Rieger E, et al. BCL2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J Invest Dermatol 1994;102: 231-235.
6. Crowson AN, Magro CM, Kadin ME, et al. Differential expression of the BCL2 oncogene in human basal cell carcinoma. Hum Pathol 1996;27: 355-359.
7. Ramdial PK, Madaree A, Reddy R, et al. BCL2 protein expression in aggressive and non-aggressive basal cell carcinomas. J Cutan Pathol 2000;27: 283-291.
8. Lu DW, El-Mofty SK, Wang HL. Expression of CDKN2A, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA. Mod Pathol 2003;16: 692-699.
9. Sano T, Oyama T, Kashiwabara K, et al. Expression status of CDKN2A protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153: 1741-1748.
10. Masui S, Nakatake Y, Toyooka Y, et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 2007;9: 625-635.
11. Long KB, Hornick JL. SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Hum Pathol 2009;40: 1768-1773.
12. Alvarez-Canas MC, Fernandez FA, Rodilla IG, et al. Perianal basal cell carcinoma: a comparative histologic, immunohistochemical, and flow cytometric study with basaloid carcinoma of the anus. Am J Dermatopathol 1996;18: 371-379.
13. Kreuter A, Bechara FG, Stucker M, et al. Perianal basal cell carcinoma - unusual localization of a frequent tumor. J Dtsch Dermatol Ges 2012;10: 59-61.
14. Damin DC, Rosito MA, Gus P, et al. Perianal basal cell carcinoma. J Cutan Med Surg 2002;6: 26-28.
15. Kort R, Fazaa B, Bouden S, et al. Perianal basal cell carcinoma. Int J Dermatol 1995;34: 427-428.
16. Rahbari H, Mehregan AH. Basal cell epitheliomas in usual and unusual sites. J Cutan Pathol 1979;6: 425-431.
17. Rosenthal D. Basal cell carcinoma of the anus: report of two cases. Dis Colon Rectum 1967;10: 397-400.
18. Kraus EW. Perianal basal cell carcinoma. Arch Dermatol 1978;114: 460-461.
19. Wittoesch JH, Woolner LB, Jackman RJ. Basal cell epithelioma and basaloid lesions of the anus. Surg Gynecol Obstet 1957;104: 75-80.
20. White WB, Schneiderman H, Sayre JT. Basal cell carcinoma of the anus: clinical and pathological distinction from cloacogenic carcinoma. J Clin Gastroenterol 1984;6: 441-446.
21. Espana A, Redondo P, Idoate MA, et al. Perianal basal cell carcinoma. Clin Exp Dermatol 1992;17: 360-362.
22. Kyzer S, Alfandari C, Bayer I, et al. Basal cell carcinoma occurring in the perianal region. Plast Reconstr Surg 1992;89: 379-380.
23. Simo AC, Jarjous N, Boddaert A, et al. [Perianal basal cell carcinoma extending into the anal canal]. Gastroenterol Clin Biol 2008;32: 337-338.
24. Nagendra Naidu DV, Rajakumar V. Perianal basal cell carcinoma - an unusual site of occurrence. Indian J Dermatol 2010;55: 178-180.
25. Shaikh FM, Healy VC, Kavanagh EG. A common tumor, an uncommon location. Gastroenterology 2010;139:e5-e6.
26. Montagliani L, Aubert P, Vergeau B, et al. [Perianal basal cell carcinoma]. Presse Med 2004;33: 389-390.
27. Gibson GE, Ahmed I. Perianal and genital basal cell carcinoma: a clinicopathologic review of 51 cases. J Am Acad Dermatol 2001;45: 68-71.
28. Paterson CA, Young-Fadok TM, Dozois RR. Basal cell carcinoma of the perianal region: 20-year experience. Dis Colon Rectum 1999;42: 1200-1202.
29. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006; 19(Suppl 2):S127-S147.
30. Morales-Ducret CR, van de Rijn M, LeBrun DP, et al. BCL2 expression in primary malignancies of the skin. Arch Dermatol 1995;131: 909-912.
31. Allal AS, Waelchli L, Brundler MA. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin Cancer Res 2003;9: 6489-6496.
32. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002;15: 6-10.
33. Bircan S, Candir O, Kapucoglu N, et al. The expression of TP63 in basal cell carcinomas and association with histological differentiation. J Cutan Pathol 2006;33: 293-298.
34. Kaufmann O, Fietze E, Mengs J, et al. Value of TP63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116: 823-830.
35. Duggan MA, Boras VF, Inoue M, et al. Human papillomavirus DNA determination of anal condylomata, dysplasias, and squamous carcinomas with in situ hybridization. Am J Clin Pathol 1989;92: 16-21.
36. Palefsky JM, Holly EA, Gonzales J, et al. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res 1991;51: 1014-1019.
37. Eshkoor SA, Ismail P, Rahman SA, et al. CDKN2A gene expression in basal cell carcinoma. Arch Med Res 2008;39: 668-673.
38. Conscience I, Jovenin N, Coissard C, et al. CDKN2A is overexpressed in cutaneous carcinomas located on sun-exposed areas. Eur J Dermatol 2006;16: 518-522.
39. Svensson S, Nilsson K, Ringberg A, et al. Invade or proliferate? Two contrasting events in malignant behavior governed by CDKN2A(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res 2003;63: 1737-1742.
40. Ishii Y, Rex M, Scotting PJ, et al. Region-specific expression of chicken Sox2 in the developing gut and lung epithelium: regulation by epithelial-mesenchymal interactions. Dev Dyn 1998;213: 464-475.
41. Sholl LM, Barletta JA, Yeap BY, et al. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 2010;34: 1193-1198.
42. Matsuoka J, Yashiro M, Sakurai K, et al. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res 2012;174: 130-135.
43. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, et al. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 2007;20: 474-481.
44. Wang X, Liang Y, Chen Q, et al. Prognostic significance of SOX2 expression in nasopharyngeal carcinoma. Cancer Invest 2012;30: 79-85.
45. Chen PL, Chen WS, Li J, et al. Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas. Mod Pathol 2012;26: 44-53.
46. Hu X, Ghisolfi L, Keates AC, et al. Induction of cancer cell stemness by chemotherapy. Cell Cycle 2012;11: 2691-2698.
47. Ward J. Five cases of basal-cell carcinoma of the vulva. J Obstet Gynaecol Br Emp 1956;63: 697-705.
48. Noodleman FR, Pollack SV. Trauma as a possible etiologic factor in basal cell carcinoma. J Dermatol Surg Oncol 1986;12: 841-846.
49. Strickland PT, Creasia D, Kripke ML. Enhancement of two-stage skin carcinogenesis by exposure of distant skin to UV radiation. J Natl Cancer Inst 1985;74: 1129-1134.